Advertising of antihypertensive medicines and prescription sales in Australia

Internal Medicine Journal

Volumn 39, Issue 11, 2009, Pages 728-732

  Vitry, A ^a   Lai, Y H ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Advertising; Antihypertensive medicine; Prescription sale; Promotion

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; METHYLDOPA; METOPROLOL; MINOXIDIL; PRAZOSIN; RAMIPRIL; THIAZIDE DIURETIC AGENT;

ARTICLE; AUSTRALIA; CLINICAL RESEARCH; CORRELATION ANALYSIS; DRUG MARKETING; LINEAR REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCIENTIFIC LITERATURE; TIME SERIES ANALYSIS;

ADVERTISING AS TOPIC; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; DRUG PRESCRIPTIONS; HUMANS; RETROSPECTIVE STUDIES;

EID: 71049146068     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01909.x     Document Type: Article

References (11)

1. Nelson MR, McNeil JJ, Peeters A, Reid CM, Krum H. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998. Med J Aust 2001 174 : 565 568.
2. Norris P, Herxheimer A, Mansfield P, Lexchin J. Drug Promotion: What We Know and What We Have Yet to Learn. Geneva : World Health Organization and Health Action International 2004. WHO/EDM/PAR/2004.3. [cited 2009 March 2]. Available from: URL: http://www.who.int/medicinedocs/en/d/Js8109e/
3. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001 323 : 1 7.
4. Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985-1996. Circulation 1999 99 : 2055 2057.
5. Charbit O. Influence de la publicité pharmaceutique sur la prescription [thesis]. Toulouse: University Paul Sabatier 2003.
6. Austin P. Changes in prescribing patterns following publication of the ALLHAT trial. JAMA 2004 291 : 44 5.
7. Xie F, Petitti D, Chen W. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. Am J Hypertens 2005 18 : 464 469.
8. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 355 : 253 259. Erratum in: Lancet 2000; 356: 860.
9. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 2003 115 : 467 472.
10. Horn FE, Mandryk JA, Mackson JM, Wutzke SE, Weekes LM, Hyndman RJ. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf 2007 16 : 297 308.
11. Greving J, Denig P, van der Veen W, Beltman F, Sturkenboom M, Haaijer-Ruskamp F. Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Soc Sci Med 2006 63 : 2890 2898.